logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris Says AEZS-136 Showed Synergy, Efficacy In Human Tumor Cells

Aeterna Zentaris Inc. (AEZS: Quote, AEZ.TO) said that a poster on its novel orally active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, showed the compound's unique inhibition and excellent activity against PI3K and Erk signaling pathways, as well as being well tolerated.

According to the company, AEZS-136 was well tolerated and showed dose-dependent inhibition of human colon tumor growth of up to 72% in a Hct116 mouse model.

Aeterna Zentaris noted that the anti-proliferative efficacy of AEZS-136 was evaluated in more than 40 human tumor cell lines including breast, ovary, endometrium, multiple myeloma, lung, melanoma, colon, leukemia and prostate cancer cells. In vitro ADMET properties were also widely assessed, while in vivo pharmacokinetics and anti-tumor efficacy was explored.

Juergen Engel, Aeterna Zentaris' President and CEO, commented, "The preclinical data presented yesterday, confirms that AEZS-136 has a unique advantageous dual PI3K /Erk kinase inhibition profile which could prove to be more efficient than single pathway inhibition. Furthermore, AEZS-136 has shown to be well tolerated.

Following these encouraging preclinical data, we are currently moving this promising compound into the clinical development stage."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fortune has once again named Google Inc. (GOOG, GOOGL) as the best company to work for, with Twitter Inc. (TWTR) also joining the annual list for the first time. This is for the sixth time and for the fourth consecutive time that Google has ranked No.1 in the Fortune's annual list of "100 Best Companies... Dunkin' Donuts has agreed to remove a whitening agent called titanium dioxide, commonly a source of nanomaterials, from all powdered sugar used in its donuts. The move follows pressure from advocacy group As You Sow, which put a shareholder proposal asking Dunkin' to reduce the risks of using nanomaterials in its food products. Warren Buffett's Berkshire Hathaway is reportedly planning its first ever European bond sale of 3 billion euros to take advantage of low interest rates in the region, traversing a path taken by a range of home companies in search of cheap funding options. The move comes as the European Central Bank's bond-buying stimulus program of 60 billion euros a month is imminent.
comments powered by Disqus
Follow RTT